ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
An Effective Oral Drug Delivery Route for Pharmacokinetic Complications: Spirulina Lipid Nanotechnology System.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microalgae as novel drug-delivery system for biomedical field.Drug delivery · 2026Review
- An Effective Oral Drug Delivery Route for Pharmacokinetic Complications: Spirulina Lipid Nanotechnology System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder characterized by mental manifestations, abdominal pain, and alterations in defecation habits. The incidence rate in some areas even exceeds 20%. Secondary to chronic, recurrent gastrointestinal motility dysfunction, for patients with IBS, upon oral administration of drugs, the fluctuation of bioavailability is typically far more significant than that of healthy individuals. Nevertheless, at present, few studies have put forward targeted drug delivery systems addressing this aspect. In this study, an oral spirulina nanotechnology System (SP@TIIAn) is developed that integrates tanshinone IIA liposome with spirulina for enhanced IBS treatment. Owing to the passive targeting of intestinal villi and enhanced adhesion by spirulina and nanoparticles, it is discovered that, in contrast to enteric-coated capsules, this system is more beneficial for guaranteeing the pharmacokinetic stability of IBS. SP@TIIAn effectively treats multiple gut-brain symptoms of IBS, contributing to providing new alternatives for the development of clinical medications for IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.